MX2010012037A - Composiciones y uso utiles para tratar trastornos cognitivos. - Google Patents

Composiciones y uso utiles para tratar trastornos cognitivos.

Info

Publication number
MX2010012037A
MX2010012037A MX2010012037A MX2010012037A MX2010012037A MX 2010012037 A MX2010012037 A MX 2010012037A MX 2010012037 A MX2010012037 A MX 2010012037A MX 2010012037 A MX2010012037 A MX 2010012037A MX 2010012037 A MX2010012037 A MX 2010012037A
Authority
MX
Mexico
Prior art keywords
disorder
compound
composition according
cognitive
phenylindan
Prior art date
Application number
MX2010012037A
Other languages
English (en)
Spanish (es)
Inventor
Rene Holm
Christine Kau
Birgitte Willumsen
Klaus Peter Hertel
Karina Kroejer Soeby
Christina Kurre Olsen
Lone Bruun
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MX2010012037A publication Critical patent/MX2010012037A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2010012037A 2008-05-07 2009-05-07 Composiciones y uso utiles para tratar trastornos cognitivos. MX2010012037A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200800647 2008-05-07
DKPA200801392 2008-10-03
DKPA200801519 2008-11-04
PCT/DK2009/050107 WO2009135495A1 (en) 2008-05-07 2009-05-07 Method for treating cognitive deficits

Publications (1)

Publication Number Publication Date
MX2010012037A true MX2010012037A (es) 2010-11-30

Family

ID=40870955

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012037A MX2010012037A (es) 2008-05-07 2009-05-07 Composiciones y uso utiles para tratar trastornos cognitivos.

Country Status (15)

Country Link
US (2) US20090306092A1 (cg-RX-API-DMAC7.html)
EP (1) EP2285377A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011519873A (cg-RX-API-DMAC7.html)
KR (1) KR20110021754A (cg-RX-API-DMAC7.html)
CN (1) CN102065861B (cg-RX-API-DMAC7.html)
AU (1) AU2009243813B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0912223A2 (cg-RX-API-DMAC7.html)
CA (1) CA2722374A1 (cg-RX-API-DMAC7.html)
CO (1) CO6311083A2 (cg-RX-API-DMAC7.html)
EA (1) EA018927B1 (cg-RX-API-DMAC7.html)
IL (1) IL209084A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010012037A (cg-RX-API-DMAC7.html)
NZ (1) NZ589571A (cg-RX-API-DMAC7.html)
WO (1) WO2009135495A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007912B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2732613A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
TWI552751B (zh) * 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法
HUE030883T2 (en) 2011-06-20 2017-06-28 H Lundbeck As Deuterated 1-piperazino-3-phenylindanes for the treatment of schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US20210395208A1 (en) * 2018-10-29 2021-12-23 H. Lundeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031216A (en) * 1974-08-12 1977-06-21 Knoll A.G. Chemische Fabriken 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
DE3139970A1 (de) * 1981-10-08 1983-04-28 Boehringer Mannheim Gmbh, 6800 Mannheim Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5026853A (en) * 1987-04-01 1991-06-25 Janssen Pharmaceutica N.V. 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
CA2132411A1 (en) * 1994-09-19 1996-03-20 Michael Trani Enzymatic esterification of long-chain racemic acids and alcohols
US6410794B1 (en) * 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) * 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
DK1073618T3 (da) * 1998-05-01 2004-03-15 Pfizer Prod Inc Fremgangsmåde til fremstilling af enantiomerisk ren eller optisk beriget sertralin-tetralon under anvendelse af kontinuerlig kromatografi
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
IN187170B (cg-RX-API-DMAC7.html) * 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
WO2003057151A2 (en) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
WO2004039322A2 (en) * 2002-10-29 2004-05-13 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
BRPI0413595B8 (pt) * 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TW200640891A (en) * 2005-02-16 2006-12-01 Lundbeck & Co As H Tartrate and malate salts of a pharmarceutical compound
WO2006086985A1 (en) * 2005-02-16 2006-08-24 H. Lundbeck A/S Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
TW200817400A (en) * 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CA2732613A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation

Also Published As

Publication number Publication date
AU2009243813B2 (en) 2014-05-29
EA018927B1 (ru) 2013-11-29
IL209084A0 (en) 2011-01-31
US20110207744A1 (en) 2011-08-25
JP2011519873A (ja) 2011-07-14
BRPI0912223A2 (pt) 2015-10-06
CN102065861B (zh) 2013-10-16
EA201071273A1 (ru) 2011-06-30
NZ589571A (en) 2012-07-27
WO2009135495A1 (en) 2009-11-12
EP2285377A1 (en) 2011-02-23
CN102065861A (zh) 2011-05-18
CO6311083A2 (es) 2011-08-22
CA2722374A1 (en) 2009-11-12
ZA201007912B (en) 2012-02-29
HK1157674A1 (en) 2012-07-06
AU2009243813A1 (en) 2009-11-12
KR20110021754A (ko) 2011-03-04
US20090306092A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
MX2010012037A (es) Composiciones y uso utiles para tratar trastornos cognitivos.
Costall et al. Anxiolytic potential of 5‐HT3 receptor antagonists
Ishibashi et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity
Miyamoto et al. Antipsychotic drugs
Costa-Campos et al. Anxiolytic properties of the antipsychotic alkaloid alstonine
Meneses et al. 5-HT1AReceptors Modulate the Consolidation of Learning in Normal and Cognitively Impaired Rats
KR20110081176A (ko) 경구용 제형물
US20250319095A1 (en) Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen
WO2021016369A1 (en) Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
JP2016516794A (ja) 不安障害患者の治療のためのナルメフェン
Takahashi et al. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for σ receptors
Tachere et al. Beyond anxiety and agitation: A clinical approach to akathisia
Mitchell et al. Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats
TW200946142A (en) Tablet
EP2714040A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
Soleimani et al. Probiotic add-on therapy in the first-episode schizophrenia: a randomized controlled trial
Maguire Impact of antipsychotics on geriatric patients: efficacy, dosing, and compliance
Sabahi et al. The effect of chronic administration of buspirone, 8-ohdpat and different doses of fluoxetine on haloperidol induced extrapyramidal disorders and general locomotor activity in male rats
HK1157674B (en) Use of trans-4((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine for improving cognition
Kitaichi et al. Involvement of the serotonergic neuronal system in phencyclidine-induced place aversion in rats
Svensson et al. Atypical antipsychotic-like effect of AMPA receptor antagonists in the rat
Burroughs Assessment of Dopaminergic and Serotonergic Receptor Antagonists in Male Rats Trained to Discriminate 4-Methylmethcathinone (Mephedrone)
Rappard et al. P. 3. c. 056 Efficacy of ziprasidone in the treatment of schizoaffective disorder: an analysis of 2 fixed-dose, placebo-controlled trials
EA049112B1 (ru) Использование бензодиазепинов для повышения чувствительности к псилоцибину после длительного приема сиозс
Julia Cain et al. Symptom Control in Stem Cell Transplantation: A Multidisciplinary Palliative Care Team Approach

Legal Events

Date Code Title Description
FA Abandonment or withdrawal